ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,625Medicare Part D Prescriptions Filled, Including Refills

Rank: 38 out of 546

$646K Total Retail Price of All Prescriptions

Rank: 27 out of 546

350 Patients Receiving at Least One Drug in Part D
75%Patients 65 Years and Older
73% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maine
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 350 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

12% of this provider’s 350 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 6,125 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

29% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$75 was the average price of a prescription from this provider, compared to $65 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maine
LEVOTHYROXINE SODIUM 363 276 1 3
LISINOPRIL 313 251 2 1
ATORVASTATIN CALCIUM 257 175 3 11
PANTOPRAZOLE SODIUM 249 163 4 18
LOSARTAN POTASSIUM 230 209 5 24
SIMVASTATIN 227 186 6 2
OMEPRAZOLE 225 175 7 4
GABAPENTIN 204 150 8 16
METOPROLOL TARTRATE 189 169 9 6
OXYCODONE HCL 182 93 S2 10 15
CRESTOR 181 133 11 36
SERTRALINE HCL 175 120 12 14
AMLODIPINE BESYLATE 173 133 13 9
FUROSEMIDE 163 124 14 5
HYDROCODONE-ACETAMINOPHEN 131 64 S3 15 8
PREDNISONE 125 87 16 29
ALLOPURINOL 118 83 17 41
CYMBALTA 116 49 18 37
METOPROLOL SUCCINATE 114 102 19 17
SPIRIVA 112 70 20 28
METFORMIN HCL 107 72 21 10
WARFARIN SODIUM 106 91 22 13
ZOLPIDEM TARTRATE 105 52 23 26
PROAIR HFA 103 55 24 27
NEXIUM 100 54 25 52
ZETIA 91 52 26 81
ISOSORBIDE MONONITRATE ER 89 66 27 32
FLUOXETINE HCL 86 34 28 39
PRAVASTATIN SODIUM 85 81 29 33
HYDROCHLOROTHIAZIDE 84 73 30 7
FLUTICASONE PROPIONATE 81 45 31 42
ATENOLOL 80 74 32 12
ESCITALOPRAM OXALATE 76 67 33 66
ADVAIR DISKUS 72 41 34 20
DIGOXIN 71 67 35 62
RANITIDINE HCL 70 56 36 23
GLIPIZIDE XL 66 48 37 191
CITALOPRAM HBR 62 60 38 21
ACTONEL 61 35 39 163
AMITRIPTYLINE HCL 61 53 R 39 48
KLOR-CON M20 61 46 39 57
MELOXICAM 56 42 42 58
BENICAR 56 41 42 162
AZITHROMYCIN 55 38 44 55
OXYBUTYNIN CHLORIDE ER 54 41 45 105
LANTUS 53 38 46 46
VENTOLIN HFA 53 17 46 63
GLIPIZIDE 50 42 48 44
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 28, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.